NasdaqGS:ENTA

Stock Analysis Report

Executive Summary

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases.

Snowflake

Fundamentals

Excellent balance sheet with acceptable track record.

Risks

  • Enanta Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Enanta Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.1%

NasdaqGS:ENTA

-2.7%

US Biotechs

-1.9%

US Market


1 Year Return

-24.0%

NasdaqGS:ENTA

-11.8%

US Biotechs

-3.3%

US Market

ENTA underperformed the Biotechs industry which returned -11.5% over the past year.

ENTA underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

ENTAIndustryMarket
7 Day-3.1%-2.7%-1.9%
30 Day-10.2%-1.5%-6.2%
90 Day-25.0%0.08%0.3%
1 Year-24.0%-24.0%-11.1%-11.8%-1.1%-3.3%
3 Year211.6%211.6%8.7%4.9%37.9%28.9%
5 Year66.6%66.6%1.9%-2.8%50.8%34.1%

Price Volatility Vs. Market

How volatile is Enanta Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Enanta Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

21.11x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Enanta Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Enanta Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

Enanta Pharmaceuticals is overvalued based on earnings compared to the US Biotechs industry average.

Enanta Pharmaceuticals is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Enanta Pharmaceuticals earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

Enanta Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Enanta Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

-67.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Enanta Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Enanta Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Enanta Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Enanta Pharmaceuticals performed over the past 5 years?

0.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Enanta Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.

Enanta Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Enanta Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the US Biotechs industry average.


Return on Equity

Enanta Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Enanta Pharmaceuticals used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Enanta Pharmaceuticals has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Enanta Pharmaceuticals's financial position?


Financial Position Analysis

Enanta Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Enanta Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Enanta Pharmaceuticals's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.1% vs 0.4% today).

Debt is well covered by operating cash flow (5602.8%, greater than 20% of total debt).

Enanta Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 277.2x debt.


Next Steps

Dividend

What is Enanta Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Enanta Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Enanta Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Enanta Pharmaceuticals has not reported any payouts.

Unable to verify if Enanta Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Enanta Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Enanta Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

15.9yrs

Average management tenure


CEO

Jay Luly (63yo)

16.1yrs

Tenure

US$4,508,737

Compensation

Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxford Bioscien ...


CEO Compensation Analysis

Jay's remuneration is about average for companies of similar size in United States of America.

Jay's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

15.9yrs

Average Tenure

64yo

Average Age

The average tenure for the Enanta Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.6yrs

Average Tenure

61.5yo

Average Age

The tenure for the Enanta Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Paul Mellett (64yo)

    Senior VP of Finance & Administration and CFO

    • Tenure: 15.9yrs
    • Compensation: US$1.42m
  • Jay Luly (63yo)

    President

    • Tenure: 16.1yrs
    • Compensation: US$4.51m
  • Yat Or (67yo)

    Senior VP of Research & Development and Chief Scientific Officer

    • Tenure: 19.8yrs
    • Compensation: US$1.52m
  • Nathaniel Gardiner (65yo)

    Senior VP

    • Tenure: 5.3yrs
    • Compensation: US$1.38m
  • Nathalie Adda (53yo)

    Senior VP & Chief Medical Officer

    • Tenure: 4.2yrs
    • Compensation: US$1.51m
  • Carol Miceli

    Director of Investor Relations

    • Tenure: 0.0yrs

Board Members

  • Bruce L. Carter (76yo)

    Non-Executive Chairman

    • Tenure: 3.7yrs
    • Compensation: US$394.19k
  • Jay Luly (63yo)

    President

    • Tenure: 16.1yrs
    • Compensation: US$4.51m
  • Terry Vance (61yo)

    Independent Director

    • Tenure: 8.2yrs
    • Compensation: US$374.19k
  • Kris Peterson (60yo)

    Independent Director

    • Tenure: 1.9yrs
    • Compensation: US$205.85k
  • George Golumbeski (62yo)

    Independent Director

    • Tenure: 5.5yrs
    • Compensation: US$366.69k
  • Lesley Russell (58yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$361.69k

Company Information

Enanta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Enanta Pharmaceuticals, Inc.
  • Ticker: ENTA
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.376b
  • Shares outstanding: 19.68m
  • Website: https://www.enanta.com

Number of Employees


Location

  • Enanta Pharmaceuticals, Inc.
  • 500 Arsenal Street
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENTANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2013
9EPDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2013

Biography

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/26 00:51
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.